Complete response with pembrolizumab in recurrent squamous cell carcinoma of the oral tongue: A case report

Jocelyn Y Cheng; Robert C Hsu; Jorge J Nieva; Jacob S Thomas

doi:10.1016/j.oraloncology.2023.106597

Complete response with pembrolizumab in recurrent squamous cell carcinoma of the oral tongue: A case report

Oral Oncol. 2023 Dec:147:106597. doi: 10.1016/j.oraloncology.2023.106597. Epub 2023 Oct 17.

Authors

Jocelyn Y Cheng¹, Robert C Hsu², Jorge J Nieva², Jacob S Thomas³

Affiliations

¹ Keck School of Medicine, University of Southern California, 1975 Zonal Avenue, Los Angeles, CA 90033, USA. Electronic address: [email protected].
² Division of Medical Oncology - Head and Neck, USC Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, NTT3440, Los Angeles, CA 90033, USA.
³ Division of Medical Oncology - Head and Neck, USC Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, NTT3440, Los Angeles, CA 90033, USA. Electronic address: [email protected].

PMID: 37857230
DOI: 10.1016/j.oraloncology.2023.106597

Abstract

Immunotherapies such as immune checkpoint inhibitors have shown promising results in solid tumors associated with BRCA2, but there are no consistent predictors for who will respond to immunotherapy. More research is needed on the impact of this mutation in head and neck squamous cell carcinomas, particularly for recurrent/metastatic tumors. We report a case of stage IV oral squamous cell carcinoma associated with BRCA2 mutation that achieved complete remission with pembrolizumab treatment for relapsed disease.

Keywords: BRCA2; Pembrolizumab; Squamous cell carcinoma of the tongue.

Publication types

Case Reports
Letter

MeSH terms

Carcinoma, Squamous Cell* / pathology
Chronic Disease
Head and Neck Neoplasms*
Humans
Mouth Neoplasms*
Neoplasm Recurrence, Local / pathology
Squamous Cell Carcinoma of Head and Neck / drug therapy

Substances

pembrolizumab